Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Dec;63(12):1657-1667.
doi: 10.1111/ijd.17366. Epub 2024 Jul 4.

Quality of life measurement in assessing treatment effectiveness in urticaria: European experts position statement

Pavel Viktorovich Chernyshov  1 , Lucia Tomas-Aragones  2 , Torsten Zuberbier  3   4 , Emek Kocatürk  3   4   5 , Liana Manolache  6 , Nives Pustisek  7 , Åke Svensson  8 , Servando E Marron  9 , Francesca Sampogna  10 , Anthony Bewley  11   12 , Carmen Salavastru  13 , Dimitra Koumaki  14 , Matthias Augustin  15 , Dennis Linder  16 , Damiano Abeni  10 , Sam S Salek  17 , Jacek C Szepietowski  18 , Gregor B Jemec  19
Affiliations
Review

Quality of life measurement in assessing treatment effectiveness in urticaria: European experts position statement

Pavel Viktorovich Chernyshov et al. Int J Dermatol. 2024 Dec.

Abstract

In this study, the European Academy of Dermatology and Venereology (EADV) Task Forces on Quality of Life and Patient-Oriented Outcomes and Urticaria and Angioedema has examined the Health-Related Quality of Life (HRQoL) measurement in the treatment of urticaria. The Dermatology Life Quality Index was the most frequently used HRQoL instrument in clinical trials on urticaria. Many reports of clinical trials of urticaria gave no exact numeric results related to HRQoL changes, making clear conclusions and comparisons with other studies impossible. The interpretation of HRQoL impairment data is more difficult when assessed by instruments without severity stratification systems. The minimal clinically significant difference (MCID) is a more clinically oriented and relevant parameter than depending on statistically significant changes in HRQoL scores. Therefore, using HRQoL instruments with established MCID data in clinical trials and clinical practice is preferred.

Keywords: measurement; quality of life; treatment; urticaria.

PubMed Disclaimer

References

    1. Fricke J, Ávila G, Keller T, Weller K, Lau S, Maurer M, et al. Prevalence of chronic urticaria in children and adults across the globe: systematic review with meta‐analysis. Allergy. 2020;75:423–432.
    1. Goldstein S, Eftekhari S, Mitchell L, Winders TA, Kaufman L, Dudas D, et al. Perspectives on living with chronic spontaneous urticaria: from onset through diagnosis and disease management in the US. Acta Derm Venereol. 2019;99:1091–1098.
    1. Bilgic A, Özdemir A, Kuteyla Can P, Koyuncu MA, Dönmez L, Akman‐Karakas A, et al. Internalized stigma in chronic urticaria: a case‐control study. Australas J Dermatol. 2022;63:e262–e265.
    1. Chernyshov PV, Tomas‐Aragones L, Manolache L, Pustisek N, Darlenski R, Marron SE, et al. Bullying in persons with skin diseases. J Eur Acad Dermatol Venereol. 2024;38:752–760.
    1. Xiang YK, Fok JS, Podder I, Yücel MB, Özkoca D, Thomsen SF, et al. An update on the use of antihistamines in managing chronic urticaria. Expert Opin Pharmacother. 2024;25:551–569. https://doi.org/10.1080/14656566.2024.2345731

LinkOut - more resources